November 08, 2020

Our firm represented Allergan Aesthetics, an AbbVie Inc. (NYSE: ABBV) company, in the acquisition Luminera Derm Ltd.’s innovative dermal filler business.

Our firm, together with Covington & Burling LLP, represented Allergan Aesthetics, an AbbVie Inc. (NYSE: ABBV) company, in the acquisition of assets of Luminera Derm Ltd., including Luminera’s innovative dermal filler portfolio and R&D pipeline.
Luminera’s key value driver for the future is HArmonyCa, an innovative dermal filler intended for facial soft tissue augmentation comprised of a combination of cross-linked hyaluronic acid (HA) with embedded calcium hydroxyapatite (CaHA) microspheres.  The combination of HA and CaHA in a single product is highly differentiated in the dermal filler category. The Luminera dermal filler portfolio also includes a line of HA dermal fillers, as well CaHA based fillers commercialized across several markets.  Brands include Crystalys, Hydryalix and Hydryal.
AbbVie Inc. was represented by partners Chaim Friedland and Yoni Raff together with senior associate Avi Meer and associates Netanel Kahana and Sharon Reingwirtz.
Partner Noam Ronen and associate Shaked Shani Korenianski advised on litigation issues.
Partner Nir Keidar advised on arbitration issues.
Associate Lee Cohen advised on real estate issues.
Associates Roni Sharon Aviram and Keren Ovadia advised on employment issues.
Senior Associate Danielle Skald advised on tax issues.
Partner Assaf Harel and associate Astar Shechter advised on data privacy issues.
Partner Ziv Rotenberg advised on intellectual property issues.

For further information please see:

Hit enter to search or ESC to close